Izhar Singh Batth
Overview
Explore the profile of Izhar Singh Batth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Batth I, Huang S, Villarreal M, Gong J, Chakravarthy D, Keppler B, et al.
Int J Mol Sci
. 2021 Mar;
22(4).
PMID: 33673346
2-Methoxyestradiol (2-ME) possesses anti-tumorigenic activities in multiple tumor models with acceptable tolerability profile in humans. Incomplete understanding of the mechanism has hindered its development as an anti-tumorigenic compound. We have...
2.
Li H, Meng Q, Noh H, Batth I, Somaiah N, Torres K, et al.
Cancer Lett
. 2017 Jun;
403:216-223.
PMID: 28652021
Circulating tumor cells (CTCs) enter the vasculature or lymphatic system after shedding from the primary tumor. CTCs may serve as "seed" cells for tumor metastasis. The utility of CTCs in...
3.
Li H, Batth I, Qu X, Xu L, Song N, Wang R, et al.
Mol Cancer
. 2017 Feb;
16(1):6.
PMID: 28137302
The insulin-like growth factor-I (IGF-I) signaling induces epithelial to mesenchymal transition (EMT) program and contributes to metastasis and drug resistance in several subtypes of tumors. In preclinical studies, targeting of...
4.
Satelli A, Batth I, Brownlee Z, Rojas C, Meng Q, Kopetz S, et al.
Sci Rep
. 2016 Jul;
6:28910.
PMID: 27363678
Although circulating tumor cells (CTCs) have potential as diagnostic biomarkers for cancer, determining their prognostic role in cancer patients undergoing treatment is a challenge. We evaluated the prognostic value of...
5.
Batth I, Yun H, Kumar A
Mol Carcinog
. 2015 Jul;
54(10):937-46.
PMID: 26152593
Prostate cancer (PCA) is the second leading cause of cancer-related deaths in men in the United States. It is natural for a hormone-driven malignancy such as prostate cancer that androgen...
6.
Hambright H, Batth I, Xie J, Ghosh R, Kumar A
Mol Carcinog
. 2014 Jul;
54(10):1227-34.
PMID: 25043857
Novel agents are desperately needed for improving the quality of life and 5-year survival to more than 30% for metastatic castrate-resistant prostate cancer. Previously we showed that Nexrutine, Phellodendron amurense...